Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products based on its SAR Technology platform. The platform is designed for use with copper isotopes, enabling imaging with copper-64 and therapy with copper-67. Its clinical development pipeline covers cancer indications including prostate cancer, breast cancer and neuroendocrine tumours (NETs). Its lead product, SAR-bisPSMA, is in clinical trials for the treatment of prostate cancer as a stand-alone diagnostic as well as a theranostic product; SARTATE is being developed as a diagnostic for NETs; and SAR-Bombesin (SAR-BBN) is described as a pan-cancer product.

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products based on its SAR Technology platform. The SAR Technology is described as ideally suited for use with copper isotopes, enabling optimal imaging and therapeutic characteristics of radiopharmaceutical products while addressing current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. Its clinical development pipeline is underpinned by the proprietary SAR Technology platform, enabling highly targeted theranostic radiopharmaceuticals for both the diagnosis (using copper-64) and treatment (using copper-67) of serious diseases. The pipeline covers large cancer indications such as prostate cancer and breast cancer, as well as smaller indications such as neuroendocrine tumours (NETs). Its lead product, SAR-bisPSMA, is in clinical trials for the treatment of prostate cancer as a stand-alone diagnostic as well as a theranostic product. SARTATE is being developed as a diagnostic for NETs. SAR-Bombesin (SAR-BBN) is described as a pan-cancer product. Clarity describes itself as a global leader in next-generation radiopharmaceuticals with its Targeted Copper Theranostic (TCT) platform of products, using the "perfect pairing" of copper isotopes, copper-64 for imaging and copper-67 for therapy. Its three core clinical-stage theranostic products, SAR-bisPSMA, SARTATE, and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors present on different cancer cells, and are in clinical development for the diagnosis and/or treatment of various cancers addressing unmet clinical needs. The versatility of the SAR Technology platform enables Clarity to pursue a Discovery Program focused on developing new products and new intellectual property (IP) for a range of cancers. Clarity states it has a robust IP position with a broad patent portfolio covering its platform, pipeline and products. Dr Alan Taylor joined Clarity's Board in November 2013 as Executive Chairperson. Michelle Parker joined the Company in June 2018 to lead its clinical programme and was appointed Chief Executive Officer and Managing Director in September 2024.

Clinical-stage radiopharmaceutical company developing next-generation theranostic products based on its SAR Technology platform.

• SAR-bisPSMA

  Lead product in clinical trials for the treatment of prostate cancer as a stand-alone diagnostic as well as a theranostic product.

• SARTATE

  Being developed as a diagnostic for neuroendocrine tumours (NETs).

• SAR-Bombesin (SAR-BBN)

  A pan-cancer product.

1. 1Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Diagnosticsclaritypharmaceuticals.com
2. 2Copper-Based Radiopharmaceutical Therapies and Diagnostics - Clarityclaritypharmaceuticals.com
3. 3Board of Directors - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imagingclaritypharmaceuticals.com
4. 4Careers - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imagingclaritypharmaceuticals.com
5. 5Clarity Pharmaceuticals Ltd. (Australia)wikidata.org